University of Maryland School of Medicine logo
Emergency Medicine
All Departments
UMSOM Assistant
UMEM Educational Pearls
  • Home
  • Departments
  • Emergency Medicine
  • CME
  • UMEM Educational Pearls
  • CME
  • Courses and Conferences
  • Free Open Access Medical Education
  • UMEM Educational Pearls

Search

Title: Medetomadine Withdrawal

Category: Toxicology

Keywords: medetomadine, withdrawal (PubMed Search)

Posted: 2/5/2026 by Robert Flint, MD (Updated: 2/5/2026)

The US drug supply has been found to contain medetomidine as an adulterant to heroine/fentanyl. It is a potent tranquilizer used in animals. It is an alpha 2 blocker (similar pharmacology to clonidine and xylazine).  Exposure to this drug can induce withdrawal symptoms to include anxiety, tremor, diaphoresis, nausea, vomiting, agitation, sympathetic hyperactivity, and delirium. Withdrawal can start within 4-6 hours of last use.

Treatment for withdrawal is outlined in this diagram.

References

Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal Management Lynch, Michael J. et al. Annals of Emergency Medicine, Volume 0, Issue 0


University of Maryland School of Medicine logo
  • Departments
  • Programs
  • Research Centers
  • Institutes
  • Graduate Education
  • CIBR Cores
  • Offices of the Dean
    • University of Maryland, Baltimore
    • University of Maryland Medical Center
    • Medical Alumni Association of the University of Maryland
    • Health Sciences and Human Services Library
University of Maryland School of Medicine
655 W. Baltimore Street
Baltimore, MD 21201
Contact Us

© University of Maryland School of Medicine

    • Webmaster
    • Web Accessibility
    • Site Index
    • UMB Hotline
    • Employment
    • Map